Neurocare employs its digital therapy platform (DTP) to offer patient-centered treatments for various psychological and neurological disorders. By using mental health techniques and tools like sleep assessment, therapeutics, psychotherapy, TMS, and neurofeedback, all managed through a cloud-based system, Neurocare enables clinicians to provide personalized care. The company's services are used in its own clinics across the US, Europe, and Australia, as well as in an increasing number of third-party clinics worldwide.
The company claims that patients benefit from better success of their therapy and the lower dropout rates as no other company in the world has such a comprehensive portfolio of different neuromodulation technologies and at the same time is vertically integrated through the operation of therapy centres.
The company owned 4 patents as of April 2024. Research institutes such as MIT, Harvard University, Oxford, Cambridge, London or ETH Zurich are among the customers, as well as all university hospitals in Germany.
Funding and financials
In April 2024, Neurocare group secured EUR 16 million (~USD 17 million) in venture funding from healthcare private equity firm TVM Capital Healthcare. The company expected to use the funds for international expansion, including entering the US market and establishing a presence in Saudi Arabia. Additionally, the funds will support the development of new hardware and software innovations.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.